Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31195465 | 0.88 | TBXAS1 (0.40) | TBXAS1MEN1KMT2ASMN1; SMN2GAA | |
| SCHEMBL26670573 | 0.82 | MEN1 (0.43) | TBXAS1NPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22558366 | 0.82 | MEN1 (0.43) | TBXAS1NPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29473304 | 0.82 | MEN1 (0.43) | TBXAS1NPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL19694359 | 0.79 | TBXAS1 (0.43) | TBXAS1NPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17018473 | 0.79 | KMT2A (0.43) | TBXAS1NPC1MEN1KMT2ATBXA2R | |
| SCHEMBL27711856 | 0.77 | TBXAS1 (0.41) | TBXAS1MEN1KMT2ASMN1; SMN2GAA | |
| SCHEMBL31422614 | 0.77 | ALDH1A1 (0.41) | TBXAS1NPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL26693982 | 0.77 | MEN1 (0.42) | TBXAS1NPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30092747 | 0.76 | AAK1 (0.40) | NPC1MEN1KMT2ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591341-B2 | Bicyclic and tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11591341-B2 | Bicyclic and tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| EP-3956331-A1 | BICYCLIC AND TRICYCLIC COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20200361947-A1 | BICYCLIC AND TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20200361947-A1 | BICYCLIC AND TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| WO-2020214728-A1 | BICYCLIC AND TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| US-9839641-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| US-9839641-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| US-9839641-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| US-20170128458-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC. | 2017-05-11 | — | — | US | disclosed |
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-09-20 | — | — | US | disclosed |
| WO-2007084415-A2 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| US-7056903-B2 | Carboxylic acid derivatives as IP antagonists | SYNTEX (U.S.A.) LLC (US) | 2006-06-06 | — | — | US | disclosed |
| US-20060035870-A1 | 2-[4-(1H-Indol-4-yloxymethyl)-benzyloxycarbonylamino]-3-phenyl-propionic acid; 3-Phenyl-2-[4-(quinolin-5-yloxymethyl)-benzyloxycarbonylamino]-propionic acid; urinary tract, pain, inflammation, respiratory states, edema formation, or hypotensive vascular diseases | COURNOYER RICHARD L | 2006-02-16 | — | — | US | disclosed |
| US-20050277628-A1 | Substituted thiophene carboxamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-15 | — | — | US | disclosed |
| US-6693098-B2 | CARBOXYLIC ACID OR TETRAZOLE DERIVATIVES CONTAINING CARBAMATE GROUPS ARE USEFUL FOR TREATING THE CONDITIONS ASSOCIATED WITH THE URINARY TRACT, PAIN, INFLAMMATION, RESPIRATORY STATES, EDEMA FORMATION OF HYPOTENSIVE VASCULAR DISEASES | SYNTEX (U.S.A) LLC | 2004-02-17 | — | — | US | disclosed |
| US-20030220367-A1 | Carboxylic acid derivatives as IP antagonists | COURNOYER RICHARD LEO (US) | 2003-11-27 | — | — | US | disclosed |
| EP-1265853-A1 | CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2002-12-18 | — | — | EP | disclosed |
| US-20010056100-A1 | Carboxylic acid derivatives as IP antagonists | SYNTEX (U.S.A.) LLC | 2001-12-27 | — | — | US | disclosed |
| WO-2001068591-A1 | CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | TBXAS1 746/4885NPC1 561/4885MEN1 1617/4885 |
| US-20060035870-A1 | 2-[4-(1H-Indol-4-yloxymethyl)-benzyloxycarbonylamino]-3-phenyl-propionic acid; 3-Phenyl-2-[4-(quinolin-5-yloxymethyl)-benzyloxycarbonylamino]-propionic acid; urinary tract, pain, inflammation, respiratory states, edema formation, or hypotensive vascular diseases | AGTR1, AGTR2, PTGIR | TBXAS1 150/4885NPC1 3982/4885MEN1 4055/4885 |
| US-20030220367-A1 | Carboxylic acid derivatives as IP antagonists | GABRP, GPBAR1, FFAR1 | TBXAS1 416/4885NPC1 1848/4885MEN1 2412/4885 |
| US-20010056100-A1 | Carboxylic acid derivatives as IP antagonists | GABRP, GPBAR1, FFAR1 | TBXAS1 404/4885NPC1 1903/4885MEN1 2555/4885 |
| US-20200361947-A1 | BICYCLIC AND TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | TBXAS1 371/4885NPC1 15/4885MEN1 376/4885 |
| US-20050277628-A1 | Substituted thiophene carboxamides | OTC, SLC22A8, DDC | TBXAS1 1458/4885NPC1 2769/4885MEN1 2017/4885 |
| US-20170128458-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | NISCH, ELANE, ALPI | TBXAS1 1275/4885NPC1 356/4885MEN1 1427/4885 |
| US-11591341-B2 | Bicyclic and tricyclic compounds | SLC10A1, PKD1, CYP11B2 | TBXAS1 371/4885NPC1 15/4885MEN1 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.